子宫内膜癌保留生育功能治疗  

Fertility-sparing treatment for endometrial cancer

作　　者：郝敏[1] 侯勇丽[1] HAO Min;HOU Yong-li(Obstetrics and Gynecology Department of the Second Hospital of Shanxi Medical University,Taiyuan 030000,China)

机构地区：[1]山西医科大学第二医院妇产科,山西太原030000

出　　处：《中国实用妇科与产科杂志》2025年第3期280-284,共5页Chinese Journal of Practical Gynecology and Obstetrics

基　　金：国家自然科学基金(81972452)。

摘　　要：子宫内膜癌作为第二大常见的妇科恶性肿瘤,其发病日益年轻化,标准疗法会导致患者生育功能受损,严重降低了患者的生存质量。因此,年轻子宫内膜癌患者的保留生育功能治疗,已成为妇瘤领域的新兴关注点。特别是近年来,随着相关研究的迅速增多以及分子分型在保留生育功能治疗中的应用,子宫内膜癌的保留生育功能治疗效果得到了显著提升。文章详细探讨了子宫内膜癌保留生育功能临床治疗的最新进展,旨在为临床医师提供有价值的参考。As the second most common gynecological malignant tumor,the incidence of endometrial cancer shows a younger trend,and the standard treatment deprives patients of fertility,which greatly affects the quality of life of patients.Therefore,the fertility-sparing treatment for young endometrial cancer patients has become a new focus in the field of gynecological oncology.Especially in recent years,with the rapid increase in related researches and the application of molecular typing in fertiligy-sparing treatment,the effect of fertility-sparing treatment for endometrial cancer has been significantly improved.This article discusses the latest progress of clinical treatment for endometrial cancer in detail,aiming to provide valuable reference for clinical practitioners.

关 键 词：子宫内膜恶性肿瘤 生育功能 药物治疗 手术治疗 

分 类 号：R737.3[医药卫生—肿瘤]